Evidence map›Paper›PMID 41162981›Full record

ArticleBMC medicine2025

Pathology-interpretable radiomic model for predicting clinical outcome in patients with osteosarcoma: a retrospective, multicenter study.

Qiuping Ren, Xiao Zhang, Xuewei Wu, Heng Zhao, Yongxin Zhang, Yubin Yao, Yinping Leng, Xiaoyang Zhang, Yumeng Liu, Jijie Xiao and 9 more

Abstract readMulticenter Study
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Qiuping Ren *Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Xiao Zhang *Medical AI Lab, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xuewei Wu *Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Heng ZhaoDepartment of Radiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yongxin ZhangDepartment of Magnetic Resonance Imaging, Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Yubin YaoDepartment of Radiology, Shantou Central Hospital, Shantou, Guangdong, China.
Yinping LengDepartment of Radiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Xiaoyang ZhangCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Yumeng LiuDepartment of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Jijie XiaoDepartment of Radiology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Wenwen LiuDepartment of Radiology, Xiangtan Central Hospital, Xiangtan, Hunan, China.
Xia XieDepartment of Radiology, the Central Hospital of Yongzhou, Yongzhou, Hunan, China.
Nana PeiDepartment of Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Rongfang HeDepartment of Pathology, The First Affiliated Hospital, University of South China, Hengyang, Hunan, China.
Na TangDepartment of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Ge WenDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China. wenge@smu.edu.cn.
Xiaodong ZhangDepartment of Radiology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. ddautumn@126.com.
Shuixing ZhangDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. shui7515@126.com.
Bin ZhangDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. xld_Jane_Eyre@126.com.

Funding

China Scholarship Council 202406780065Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University JNU1AF-CFTP-2022-a01201National Key Research and Development Program of China 2023YFF1204600Outstanding Innovative Talents Cultivation Funded Programs for Doctoral Students of Jinan University 2024CXB027Outstanding Young Talents of Guangdong Special Support Program (Health Commission of Guangdong) 0720240213Science and Technology Projects in Guangzhou 202201020022Science and Technology Projects in Guangzhou 2025A04J7006
6 · The paper itself

Abstract

backgroundOsteosarcoma is the most prevalent primary malignant bone tumor. Radiomic models show promise in globally evaluating the prognosis of osteosarcoma; however, they lack biological interpretability. We aimed to develop a radiomic model using MRI to predict disease-free survival (DFS) in osteosarcoma patients and provide the underlying pathobiology of the model.

methodsThis retrospective study included 270 patients (training set, n = 166; external test set 1, n = 56; external test set 2, n = 48) with surgically treated and histology-proven osteosarcoma from 14 tertiary centers. A total of 1130 radiomic features were extracted from baseline MRI data. After dimensionality reduction, the radiomic model was developed on the training set and tested on the external test sets. The radiomics interpretability study used the hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained whole slide images (WSIs) of patients from the testing sets. Ten types of nuclear morphological features were extracted from each nucleus in H&E WSIs and aggregated into 150 patient-level features. Furthermore, five immune- and hypoxia-related IHC biomarkers, including CD3, CD8, CD68, FOXP3, and CAIX, were quantified from IHC WSIs. The correlation between the radiomic features and histopathologic markers was assessed using Spearman or Pearson correlation analysis, with multiple hypothesis testing controlled by the false discovery rate.

resultsThe radiomic model comprising 12 features yielded a time-dependent AUC of 0.916 (95% CI: 0.893-0.939), 0.802 (95% CI: 0.763-0.840), and 0.895 (95% CI: 0.869-0.920) in the training set, external test set 1, and external test set 2, respectively. Notably, nine out of 12 radiomic features exhibited significant correlations with 17 cellular features, resulting in 32 pairs. Specifically, there were four (12.5%) pairs with absolute coefficient r (|r|) between 0.3 and 0.4, 22 (68.8%) pairs between 0.4 and 0.5, and six (18.8%) pairs exceeding 0.5. Four radiomic features were correlated with CD3 (r = 0.50-0.75), two features with CD8 (r = 0.46 and 0.60), and three features with CD8/FOXP3 (r = 0.69-0.81).

conclusionsThe MRI-based radiomic model shows potential in predicting DFS in osteosarcoma patients. Most radiomic features show only moderate associations with H&E-derived nuclear morphological features; they exhibit higher correlations with immune-related biomarkers.

Indexed as

Bone NeoplasmsOsteosarcomaAdolescentAdultChildDisease-Free SurvivalFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPrognosisRadiomicsRetrospective StudiesYoung AdultDisease-free survivalHematoxylin and eosinImmunohistochemistryMagnetic resonance imagingOsteosarcomaRadiomics

Identifiers

PMID41162981
PMCPMC12573972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.